Press Release

  View printer-friendly version

« Back

Collegium Pharmaceutical Appoints Chief Financial Officer and New Member to Its Board of Directors

February 9, 2015 at 9:50 AM EST

Management team significantly strengthened by adding financial expertise

Canton, MA – February 9, 2015 – Collegium Pharmaceutical, Inc., a specialty pharmaceutical company focused on the development and commercialization of innovative abuse-deterrent treatments for chronic pain and other diseases, announced today the appointments of Paul Brannelly as Executive Vice President and Chief Financial Officer and Garen Bohlin to its Board of Directors, effective immediately.

Adding Paul to Collegium’s management team and Garen to our Board of Directors comes at a critical time as we advance our lead abuse-deterrent development program through the NDA review process,” said Michael Heffernan, President and CEO. “Both Paul and Garen’s significant experience in building both public and private life sciences companies will be invaluable as we plan for significant company growth upon FDA approval of Xtampza ER™.”

Paul Brannelly, Chief Financial Officer

Paul has held senior financial management positions for both publicly held and privately held companies, gaining significant experience raising capital, executing growth strategies and mergers and acquisitions. Paul most recently served as Senior Vice President, Finance & Administration, and Treasurer of Karyopharm Therapeutics Inc., a publicly traded specialty pharmaceutical company. Prior to joining Karyopharm, he held the position of Vice President Finance, Treasurer, and Secretary for Verastem, Incorporated, a publicly held biotechnology company. Prior to Verastem, Paul was Chief Financial Officer of Longwood Fund, a healthcare dedicated venture capital fund. Paul also held senior financial management roles with Sirtris Pharmaceuticals (acquired by GlaxoSmithKline), CombinatoRx and Dyax. With over 15 years in the biopharmaceutical industry, Paul has raised more than $700 million in public and private capital. Paul holds a Bachelors in Business Administration in Accounting from University of Massachusetts at Amherst and was a Certified Public Accountant.

Garen Bohlin, Board Member

Garen held senior executive positions with biotechnology companies for almost 30 years. In his final operating role, Garen was Executive Vice President of Constellation Pharmaceuticals. Previously, he served as Chief Operating Officer of Sirtris Pharmaceuticals, which was acquired by GlaxoSmithKline. Prior to Sirtris, he was President and Chief Executive Officer of Syntonix Pharmaceuticals, which was acquired by Biogen Idec. Prior to Syntonix, he was Executive Vice President of Genetics Institute, which was acquired by American Home Products/Wyeth. Garen played a key strategic role in each of his positions and also had substantial operational experience. Mr. Bohlin currently serves on the board of directors of Karyopharm Therapeutics Inc., Proteon Therapeutics, Inc. and Tetraphase Pharmaceuticals, Inc. and previously served as a director on the boards of five other companies.